HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Presentation for Webinar: China Healthcare - Outlook and Opportunities in 2022

Aier Eye Hospital Group (300015.CH) - More than Just Bribery Scandal

BeiGene Ltd (6160.HK/688235.CH) - There Is No Way to Retreat

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

Ascent ENT Group Holdings / Equity Capital Markets

<ul>
<li>For ENT services, the number of patients and scale of ENT field are relatively stable, with growth ceiling.</li>
<li>Due to the limited doctor resources in Singapore and the intensified multi-party competition faced by Ascent, there may not be exciting future growth potential.</li>
<li>So, we are conservative about the Company’s outlook if it just operates the business within Singapore or without diversifying its business effectively.</li>
</ul>


For ENT services, the number of patients and scale of ENT field are relatively stable, with growth ceiling.
Due to the limited doctor resources in Singapore and the intensified multi-party competition faced by Ascent, there may not be exciting future growth potential.
So, we are conservative about the Company’s outlook if it just operates the business within Singapore or without diversifying its business effectively.


Pre IPO Ascent ENT Group Holdings - Conservative About the Outlook